… Author Contributions: Drs Benotmane and Caillard had full access to all of the data in the study
… Dr Benotmane reported receiving travel grants from Novartis, Sandoz, Fresenius Medical …

2 (SARS-CoV-2) have not been specifically investigated in kidney transplant recipient (KTRs).
Preliminary results suggest that among KTRs who received the first injection of an mRNA-…

There are no studies which have compared the risk of severe COVID‐19 and related mortality
between transplant recipients and nontransplant patients. We enrolled two groups of …

To the editor: Several of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines use a nucleosidemodified, purified mRNA lipid nanoparticle-encapsulated …

Background: Kidney transplant recipients receiving immunosuppressive drugs have impaired
immune responses to messenger RNA (mRNA) COVID-19 vaccines (1). Consequently, …

Background and purpose Neurological manifestations in coronavirus disease (COVID)‐2019
may adversely affect clinical outcomes. Severe COVID‐19 and uremia are risk factors for …

The cilgavimab−tixagevimab combination retains a partial in vitro neutralizing activity against
the current SARS‐CoV‐2 variants of concern (omicron BA.1, BA.1.1, and BA.2). Here, we …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has spread widely, causing
coronavirus disease 2019 (COVID‐19) and significant mortality. However, data on viral …

To the editor: Immunocompromised patients show an impaired vaccine-induced immune
response, resulting in an increased risk of severe coronavirus disease 2019 (COVID-19). 1 In …

To the editor: After the publication of the 2 letters by Negrea and Rovin 1 and Rahim et al., 2
we herein describe 3 additional patients with IgA nephropathy (IgAN) who developed gross …